

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 January 2019

Cumulative for December 2018 and January 2019



Contents

Summary of decisions effective 1 January 2019	3
Section H changes to Part II	5
Index	12

Summary of decisions

EFFECTIVE 1 JANUARY 2019

- Afibercept (Eylea) inj 40 mg per ml, 0.1 ml vial – amended restriction criteria
- Amikacin (Biomed) inj 5 mg per ml, 5 ml syringe – amended pack size and price
- Amiloride tab 5 mg – new listing
- Amoxicillin with clavulanic acid (m-amoxiclav) inj 500 mg with clavulanic acid 100 mg vial and inj 1,000 mg with clavulanic acid 200 mg vial – price increase
- Apomorphine hydrochloride inj 10 mg per ml, 1 ml ampoule – delisted 1 January 2019
- Calcium gluconate (e.g. Max Health) inj 10%, 10 ml ampoule – new listing
- Calcium gluconate (Hospira) inj 10%, 10 ml ampoule – to be delisted 1 March 2019
- Chloramphenicol (Chlorofast) eye drops 0.5% – price increase
- Clozapine (Clozaril) tab 100 mg, 50 tab pack and 100 tab pack – listing new Pharmacodes and delisting existing Pharmacodes
- Colecalciferol (Puria) oral liq 188 mcg per ml (7,500 iu per ml) – new listing
- Desferrioxamine mesilate (DBL Desferrioxamine Mesilate for Injection BP) inj 500 mg vial – new listing and addition of HSS
- Desferrioxamine mesylate (Desferal) inj 500 mg vial – to be delisted 1 March 2019
- Desflurane (Suprane) soln for inhalation 100%, 240 ml bottle – HSS extended
- Domperidone (Pharmacy Health) tab 10 mg – new listing and addition of HSS
- Domperidone (Prokinex) tab 10 mg – to be delisted 1 March 2019
- Folic acid (Biomed) oral liq 50 mcg per ml – price increase
- Furosemide [frusemide] (Urex Forte) tab 500 mg – addition of HSS
- Hydrocortisone butyrate oint 0.1% (Locoid) and milky emul 0.1% (Locoid Crelo) – price increase and addition of HSS
- Hydrocortisone butyrate (Locoid) scalp lotn 0.1% – price increase and addition of HSS
- Hydrocortisone with natamycin and neomycin (Pimafucort) crm 1% with natamycin 1% and neomycin sulphate 0.5%, 15 g and oint 1% with natamycin 1% and neomycin sulphate 0.5%, 15 g – price increase
- Hyoscine hydrobromide (Scopoderm TTS) patch 1.5 mg – price increase
- Irinotecan hydrochloride (Irinotecan Actavis 40) inj 20 mg per ml, 2 ml vial – delisted 1 January 2019
- Isoflurane (Aerrane) soln for inhalation 100%, 250 ml bottle – HSS extended

Summary of decisions – effective 1 January 2019 (continued)

- Iron polymaltose (Ferrosig) inj 50 mg per ml, 2 ml ampoule – new listing
- Metolazone tab 5 mg – restriction removed
- Metronidazole (Baxter) inj 5 mg per ml, 100 ml bag – price increase
- Potassium iodate (NeuroTab) tab 253 mcg (150 mcg elemental iodine) – addition of HSS
- Sevoflurane (Baxter) soln for inhalation 100%, 250 ml bottle – HSS extended
- Varenicline (Varenicline Pfizer) tab 0.5 mg x 11 and 1 mg x 42 and tab 1 mg – new listing and addition of HSS
- Varenicline (Champix) tab 0.5 mg x 11 and 1 mg x 14 and tab 1 mg – to be delisted 1 March 2019

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 January 2019

ALIMENTARY TRACT AND METABOLISM

17	POTASSIUM IODATE (addition of HSS) Tab 253 mcg (150 mcg elemental iodine) – 1% DV Mar-19 to 2020	4.69	90	NeuroTabs
18	IRON POLYMALTOSE (new listing) Inj 50 mg per ml, 2 ml ampoule	34.50	5	Ferrosig
21	COLECALCIFEROL (new listing) Oral liq 188 mcg per ml (7,500 iu per ml)	9.00	4.8 ml	Puria

BLOOD AND BLOOD FORMING ORGANS

24	FOLIC ACID (↑ price) Oral liq 50 mcg per ml	26.00	25 ml	Biomed
33	CALCIUM GLUCONATE (new listing) Inj 10%, 10 ml ampoule			<i>e.g. Max Health</i>
33	CALCIUM GLUCONATE (delisting) Inj 10%, 10 ml ampoule	34.24	10	Hospira

Note – Hospira inj 10%, 10 ml ampoule to be delisted from 1 Mach 2019.

CARDIOVASCULAR SYSTEM

42	FUROSEMIDE [FRUSEMIDE] (addition of HSS) Tab 500 mg – 1% DV Mar-19 to 2021	25.00	50	Urex Forte
42	AMILORIDE HYDROCHLORIDE (new listing) Tab 5 mg			
43	METOLAZONE (restriction removed) Tab 5 mg			

Initiation

Any of the following:

- 1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or
- 2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions; or
- 3 Paediatric patient has oedema secondary to nephrotic syndrome that has not responded to loop diuretics.

DERMATOLOGICALS

54	HYDROCORTISONE BUTYRATE (↑ price and addition of HSS) Oint 0.1% – 1% DV Mar-19 to 2021	13.70	100 g	Locoid
	Milky emul 0.1% – 1% DV Mar-19 to 2021	13.70	100 ml	Locoid Crelo

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2019 (continued)

55	HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN († price)			
	Crm 1% with natamycin 1% and neomycin sulphate 0.5%	3.35	15 g	Pimafucort
	Oint 1% with natamycin 1% and neomycin sulphate 0.5%	3.35	15 g	Pimafucort
56	HYDROCORTISONE BUTYRATE († price and addition of HSS)			
	Scalp lotn 0.1% – 1% DV Mar-19 to 2021	7.30	100 ml	Locoid

INFECTIONS

72	AMIKACIN (amended pack size and price)			
	→ Inj 5 mg per ml, 5 ml syringe.....	181.50 18.15	10	Biomed
76	AMOXICILLIN WITH CLAVULANIC ACID († price)			
	Inj 500 mg with clavulanic acid 100 mg vial.....	28.18	10	m-Amoxiclav
	Inj 1,000 mg with clavulanic acid 200 mg vial.....	43.30	10	m-Amoxiclav
84	METRONIDAZOLE († price)			
	Inj 5 mg per ml, 100 ml bag.....	55.00	10	Baxter

NERVOUS SYSTEM

106	APOMORPHINE HYDROCHLORIDE (delisted)			
	Inj 10 mg per ml, 1 ml ampoule			
	Note – Apomorphine hydrochloride inj 10 mg per ml, 1 ml ampoule delisted 1 January 2019.			
107	DESFLURANE (HSS extended)			
	Soln for inhalation 100%, 240 ml bottle			
	– 1% DV Sep-16 to 2020 2019	1,350.00	6	Suprane
107	ISOFLURANE (HSS extended)			
	Soln for inhalation 100%, 250 ml bottle			
	– 1% DV Sep-16 to 2020 2019	1,020.00	6	Aerrane
108	SEVOFLURANE (HSS extended)			
	Soln for inhalation 100%, 250 ml bottle			
	– 1% DV Sep-16 to 2020 2019	840.00	6	Baxter
119	DOMPERIDONE (brand change)			
	Tab 10 mg – 1% DV Mar-19 to 2021	2.25	100	Pharmacy Health
	Note – Prokinex tab 10 mg to be delisted from 1 March 2019.			
119	HYOSCINE HYDROBROMIDE († price)			
	→ Patch 1.5 mg	14.11	2	Scopoderm TTS
120	CLOZAPINE (Pharmacode change)			
	Tab 100 mg	14.73	50	Clozaril
		29.45	100	Clozaril
	Note – New Pharmacode listings, tab 100 mg 2534878 (50 tab pack) and 2534886 (100 tab pack). Existing Pharmacodes to be delisted 1 July 2019.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2019 (continued)

129	VARENICLINE (brand change)			
	→ Tab 0.5 mg × 11 and 1 mg × 42 – 1% DV Mar-19 to 2021	25.64	53	Varenicline Pfizer
	→ Tab 1 mg – 1% DV Mar-19 to 2021	27.10	56	Varenicline Pfizer
	Note – Champix tab 0.5 mg x 11 and 1 mg x 14 and tab 1 mg (28 tab and 56 tab pack) to be delisted from 1 March 2019.			

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

135	IRINOTECAN HYDROCHLORIDE (delisted)			
	Inj 20 mg per ml, 2 ml vial.....	11.50	1	Irinotecan Actavis 40
	Note – Irinotecan Actavis 40 inj 20 mg per ml, 2 ml vial delisted from 1 January 2019.			

160	AFLIBERCEPT (amended restriction criteria – affected criteria shown only)			
	→ Inj 40 mg per ml, 0.1 ml vial.....	1,250.00	1	Eylea
	Initiation – Wet Age Related Macular Degeneration Ophthalmologist Re-assessment required after 3 months Either:			
	1 All of the following:			
	1.1 Any of the following:			
	1.1.1 Wet age-related macular degeneration (wet AMD); or			
	1.1.2 Polypoidal choroidal vasculopathy; or			
	1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and			
	1.2 Either:			
	1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or			
	1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and			
	1.3 There is no structural damage to the central fovea of the treated eye; and			
	1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or			
	2 Any of the following Either:			
	2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or			
	2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment; or			
	2.3 Patient has current approval to use ranibizumab for treatment of wAMD; or			
	2.4 Patient is currently receiving treatment with aflibercept and has documented previous poor response to bevacizumab.			

Note: Criteria 2.3 and 2.4 will be removed from 1 January 2019.

Initiation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 4 months
Either:

- † All of the following:
- †-1 Patient has centre involving diabetic macular oedema (DMO); and
 - †-2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
 - †-3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
 - †-4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and

continued...

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2019 (continued)

continued...

- 1-5 There is no centre-involving sub-retinal fibrosis or foveal atrophy; or
 2 Patient is currently receiving treatment with aflibercept and has documented previous poor response to bevacizumab.
 Note: Criterion 2 will be removed from 1 January 2019.

SENSORY ORGANS

197	CHLORAMPHENICOL (↑ price) Eye drops 0.5%	1.95	10 ml	Chlorafast
-----	---	------	-------	------------

VARIOUS

205	DEFERRIOXAMINE MESILATE (brand change) Inj 500 mg vial – 1% DV Mar-19 to 2021	84.53	10	DBL Desferrioxamine Mesylate for Injection BP
-----	--	-------	----	--

Note – Desferal inj 500 mg vial to be delisted from 1 March 2019.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 December 2018

ALIMENTARY TRACT AND METABOLISM

10	METFORMIN HYDROCHLORIDE (Brand change) Tab immediate-release 850 mg – 1% DV Feb-19 to 2021	7.04	500	Apotex
	Note – Metformin Mylan tab immediate-release 850 mg to be delisted 1 February 2019.			
10	PANCREATIC ENZYME (Pharmacode change) Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 1% DV Sep-18 to 2021	34.93	100	Creon 10000
	Note – this is a new Pharmacode listing 2535300; 954322 to be delisted from 1 May 2019.			
17	CALCIUM CARBONATE (delisting) Tab eff 1.75 g (1 g elemental).....	2.07	10	Calsource
	Note – Calsource tab eff 1.75 g (1 g elemental) to be delisted from 1 July 2019.			
18	MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE (new listing) Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium) Note – magnesium oxide with with magnesium aspartate, magnesium amino acid chelate and magnesium citrate cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium) to be delisted from 1 March 2019.			
18	MAGNESIUM AMINO ACID CHELATE (new listing) Cap 750 mg (150 mg elemental) Note – magnesium amino acid chelate cap 750 mg (150 mg elemental) to be delisted from 1 March 2019.			

HORMONE PREPARATIONS

62	TESTOSTERONE (t price) Patch 5 mg per day	90.00	30	Androderm
65	CLOMIFENE CITRATE (delisting) Tab 50 mg	29.84	10	Serophene
	Note – Serophene tab 50 mg to be delisted from 1 March 2019.			

INFECTIONS

72	AMIKACIN (t price) ➔ Inj 5 mg per ml, 5 ml syringe.....	181.50	10	Biomed
79	LINEZOLID (brand change) ➔ Inj 2 mg per ml, 300 ml bottle – 1% DV Feb-19 to 2021	18.50	1	Linezolid Kabi
	Note – Zyvox inj 2 mg per ml, 300 ml bag, 10 inj pack to be delisted 1 February 2019.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 December 2018 (continued)

MUSCULOSKELETAL SYSTEM

94	ALENDRONATE SODIUM (delisting) → Tab 40 mg.....	133.00	30	Fosamax
Note – Fosamax tab 40 mg to be delisted from 1 May 2019.				

NERVOUS SYSTEM

110	PARACETAMOL (brand change) Suppos 500 mg – 1% V Feb-19 to 2021	12.40	50	Gacet
Note – Paracare suppos 500 mg to be delisted from 1 February 2019.				
115	DIAZEPAM (↑ price) Rectal tubes 5 mg	40.87	5	Stesolid
116	LAMOTRIGINE (Pharmacode change) Tab dispersible 25 mg	19.38	56	Logem
	Tab dispersible 50 mg	32.97	56	Logem
	Tab dispersible 100 mg	56.91	56	Logem
Note – new Pharmacode listings, tab dispersible 25 mg, 2553376; tab dispersible 50 mg, 2553384 and tab dispersible 100 mg, 2553392. Existing Pharmacodes to be delisted 1 June 2019.				
120	CLOZAPINE (Pharmacode change) Tab 25 mg	5.69	50	Clozaril
Note – this is a new Pharmacode listing 2534843; 454680 to be delisted from 1 June 2019.				
121	ZIPRASIDONE (HSS reinstated) Cap 20 mg – 1% DV Dec-18 to 2021	14.50	60	Zusdone
128	DISULFIRAM (↑ price) Tab 200 mg	55.00	100	Antabuse

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

144	ABIRATERONE ACETATE (amended restriction criteria) → Tab 250 mg.....	4,276.19	120	Zytiga
Restricted				
Initiation				
Medical oncologist, radiation oncologist or urologist				
<i>Re-assessment required after 5 6 months</i>				
All of the following:				
1 Patient has prostate cancer; and				
2 Patient has metastases; and				
3 Patient's disease is castration resistant; and				
4 Either:				
4.1 All of the following:				
4.1.1 Patient is symptomatic; and				
4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and				
4.1.3 Patient has ECOG performance score of 0-1; and				
4.1.4 Patient has not had prior treatment with taxane chemotherapy; or				
4.2 All of the following:				

continued...

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 December 2018 (continued)

continued...

- 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
- 4.2.2 Patient has ECOG performance score of 0-2; and
- 4.2.3 Patient has not had prior treatment with abiraterone.

Continuation

Medical oncologist, radiation oncologist or urologist

Re-assessment required after 5 6 months

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

SENSORY ORGANS

201	BIMATOPROST (brand change) Eye drops 0.03% – 1% DV Feb-19 to 2021	3.30	3 ml	Bimatoprost Multichem
Note – Bimatoprost Actavis eye drops 0.03% to be delisted from 1 February 2019.				

Index

Pharmaceuticals and brands

A	
Abiraterone acetate	10
Aerrane	6
Aflibercept	7
Alendronate sodium	10
Amikacin	6, 9
Amiloride hydrochloride	5
Amoxicillin with clavulanic acid	6
Androderm	9
Antabuse	10
Apomorphine hydrochloride	6
B	
Bimatoprost	11
Bimatoprost Multichem	11
C	
Calcium carbonate	9
Calcium gluconate	5
Calsource	9
Chlorafast	8
Chloramphenicol	8
Clomifene citrate	9
Clozapine	6, 10
Clozaril	6, 10
Colecalciferol	5
Creon 10000	9
D	
DBL Desferrioxamine Mesylate for Injection BP	8
Desferrioxamine mesilate	8
Desflurane	6
Diazepam	10
Disulfiram	10
Domperidone	6
E	
Eylea	7
F	
Ferrosig	5
Folic acid	5
Fosamax	10
Frusemide	5
Furosemide [frusemide]	5
G	
Gacet	10
H	
Hydrocortisone butyrate	5, 6
Hydrocortisone with natamycin and neomycin	6
Hyoscine hydrobromide	6
I	
Irinotecan Actavis 40	7
Irinotecan hydrochloride	7
Iron polymaltose	5
Isoflurane	6
L	
Lamotrigine	10
Linezolid	9
Linezolid Kabi	9
Locoid	5, 6
Locoid Crelo	5
Logem	10
M	
Magnesium amino acid chelate	9
Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate	9
m-Amoxiclav	6
Metformin hydrochloride	9
Metolazone	5
Metronidazole	6
N	
NeuroTabs	5
P	
Pancreatic enzyme	9
Paracetamol	10
Pimafucort	6
Potassium iodate	5
Puria	5
S	
Scopoderm TTS	6
Serophene	9
Sevoflurane	6
Stesolid	10
Suprane	6
T	
Testosterone	9
U	
Urex Forte	5
V	
Varenicline	7
Varenicline Pfizer	7
Z	
Ziprasidone	10
Zusdone	10
Zytiga	10



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990

Fax: 64 4 460 4995

Website: www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3694 (Print)

ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand